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ABSTRACT
Purpose Despite data showing breathlessness to be 
more prevalent in older adults, we have little detail 
about the severity or multidimensional characteristics 
of breathlessness and other self- reported measures 
(such as quality of life and other cardiorespiratory- 
related symptoms) in this group at the population level. 
We also know little about the relationship between 
multidimensional breathlessness, other symptoms, 
comorbidities and future clinical outcomes such as quality 
of life, hospitalisation and mortality. This paper reports the 
design and descriptive findings from the first two waves of 
a longitudinal prospective cohort study in older adults.
Participants Between 2010 and 2011, 1900 men in a 
region in southern Sweden aged 65 years were invited 
to attend for VAScular and Chronic Obstructive Lung 
disease (VASCOL) baseline (Wave 1) assessments which 
included physiological measurements, blood sampling 
and a self- report survey of lifestyle and previous medical 
conditions. In 2019, follow- up postal survey data (Wave 
2) were collected with additional self- report measures 
for breathlessness, other symptoms and quality of life. At 
each wave, data are cross- linked with nationwide Swedish 
registry data of diseases, treatment, hospitalisation and 
cause of death.
Findings to date 1302/1900 (68%) of invited men 
participated in Wave 1, which include 56% of all 65- year- 
old men in the region. 5% reported asthma, 2% chronic 
obstructive pulmonary disease, 56% hypertension, 10% 
diabetes and 19% had airflow limitation. The VASCOL 
cohort had comparable characteristics to those of similarly 
aged men in Sweden. By 2019, 109/1302 (8.4%) had died. 
907/1193 (76%) of the remainder participated in Wave 2. 
Internal data completeness of 95% or more was achieved 
for most Wave 2 measures.
Future plans A third wave will be conducted within 
4 years, and the cohort will be followed through repeated 
follow- ups planned every fourth year, as well as national 
registry data of diagnosis, treatments and cause of death.
INTRODUCTION
Cardiorespiratory diseases, such as ischaemic 
heart disease, heart failure and chronic 
obstructive pulmonary disease (COPD), 
are major causes of morbidity and mortality 
worldwide.1 2 They often coexist with, and 
are worsened by, other conditions leading to 
poorer outcomes. Multimorbidity increases 
over the age of 65 years, particularly those 
with cardiorespiratory diseases.3–5
Cardiorespiratory diseases are associated 
with major adverse health effects including 
anxiety and depression, poorer quality of 
sleep and impaired physical capacity.6 7 Symp-
toms of cardiorespiratory diseases include 
chest pain, nausea and fatigue, with the major 
‘cardinal’ symptom being chronic breathless-
ness.8 Breathlessness is also highly prevalent 
across the older population,9 and the risk of 
developing breathlessness affecting daily life 
increases markedly with age.10 People who 
are breathless often avoid physical activities,11 
many becoming socially isolated.8 12 In COPD, 
breathlessness is a stronger predictor of 
Strengths and limitations of this study
 ► More than half (57%) of all 65- year- old men in 
Blekinge participated in the VAScular and Chronic 
Obstructive Lung disease (VASCOL) baseline, of 
which approximately 70% also participated in the 
follow- up.
 ► The VASCOL baseline, Wave 1 (n=1302), collected 
a wide range of data: physiological measurements, 
blood samples, survey of lifestyle and self- reported 
conditions.
 ► The VASCOL follow- up study, Wave 2 (n=907), in-
cluded an extensive set of validated self- report 
instruments of symptoms of cardiorespiratory 
diseases.
 ► Cross- linkage of data with national registries al-
lowed prospective study of morbidity, hospitalisation 
and mortality in this cohort.
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mortality than the level of airflow limitation.13 Breathless-
ness is also associated with impaired quality of life (QoL), 
worse physical capacity and higher overall mortality in 
people with different underlying conditions.7 8 14
Few population- level studies have focused on breath-
lessness and its relationship with other self- reported 
outcomes. The Burden of Obstructive Lung Disease 
(BOLD),15 the PLATINO16 and the European Commu-
nity Respiratory Heath Survey (ECRHS)17 studies assessed 
breathlessness mainly using the unidimensional modi-
fied Medical Research Council Scale, which thus only 
assesses the level of exertion required to induce breath-
lessness, and not the severity of the symptom per se.12 
Breathlessness is a multidimensional symptom affecting 
all domains of a person’s life18 and the intensity of both 
physical and affective dimensions needs to be included 
in measurements.7 18 For multidimensional assessment of 
breathlessness, the instruments Dyspnoea-12 (D12)19 and 
Multidimensional Dyspnoea Profile20 (MDP) can be used. 
Recently, the minimal clinically important difference was 
determined for both D12 and MDP in cardiorespiratory 
disease.21
Some breathlessness data from older adults at the 
general population level regarding prevalence and clin-
ical outcomes are published, but details including charac-
teristics, and severity are relatively few. We also know little 
about other common symptoms and comorbidities affect 
clinical outcomes such as QoL, health service utilisation 
and survival in older adults. To date, no study has assessed 
the relationship between multidimensional breathless-
ness and clinical outcomes in older adults in the general 
population.
The VAScular and Chronic Obstructive Lung disease 
(VASCOL) study is an epidemiological, longitudinal, 
cohort study to describe the relationship between vascular 
diseases and COPD. Since its beginning in 2010, the scope 
has broaden to also focus on QoL, self- reported measures 
of breathlessness and other symptoms of cardiovascular 
diseases.
In this paper, we present the VASCOL study design, 
including future longitudinal data collection, describe 
the characteristics of participants from the first two waves, 
(Wave 1—baseline; Wave 2—first follow- up).
Study objectives
The overall objective of the VASCOL study is to evaluate 
the relationship between lifestyle variables, morbidity due 
to cardiorespiratory disease, multidimensional breathless-
ness, other symptoms of cardiovascular diseases and QoL 
in a population sample of men aged 65 years on cohort 
entry. We aim to evaluate:
 ► How baseline factors (diseases, lung function, life-
style, demographics) predict the outcomes of breath-
lessness, QoL, diagnosed diseases, hospitalisation and 
mortality.
 ► The prevalence, characteristics and severity of multi-
dimensional breathlessness and other symptoms such 
as anxiety, depression, pain, nausea and fatigue.
 ► The relationship between self- reported QoL and 
symptom burden and functional limitations.
 ► Contributing causes of breathlessness and other 
symptoms such as anxiety, depression, pain, nausea 
and fatigue.
 ► How the presence and type of symptoms predicts 
future diseases.
COHORT DESCRIPTION
The VASCOL study is an ongoing longitudinal epidemi-
ological cohort study in Blekinge, Sweden. Blekinge is a 
county located in southern Sweden and has a total popu-
lation of around 160 000, of which approximately 2300 
were 65- year- old men in 2010–2011. Blekinge geographi-
cally covers both urban and rural areas with good public 
transportations, see figure 1.
In 2010–2011, 1900 men aged 65 years in Blekinge 
were invited to a screening campaign of abdominal aortic 
aneurysm at a health centre in the city of Karlshamn.
The men were informed about the VASCOL study and 
invited to give their informed written consent to partic-
ipate in the Wave 1 examinations. A self- report survey 
(demography, lifestyle and previous diseases) was included 
with the invitation pack. Blekinge’s biggest municipality, 
Karlskrona, was not included in the screening campaign 
until 2011, resulting in approximately 80% (1900/2300) 
of all 65- year- old men living in Blekinge 2010–2011 were 
invited to participate in the VASCOL study. The inclu-
sion criteria were: men, 65 years old, living in Blekinge 
(excluding Karlskrona in 2010), participating in the 
screening examinations and willing to give a written 
consent to participate in the Wave 1 examinations. There 
were no exclusion criteria based on any conditions. In 
2019, a follow- up postal survey was sent out to the partici-
pants still alive and with a known address (Wave 2).
Wave 1: baseline data collection
At baseline, a clinical visit was performed, and data 
from the self- report survey collected. Nurses checked 
for survey data completeness, and those who omitted to 
bring their survey were also able to complete this during 
the visit. Physiological measurements and blood sampling 
were collected according to standard protocols by regis-
tered nurses. The blood samples were stored in a biobank 
for future analysis. Out of the 1900 men attending the 
screening, 1302 (68.5%) participated in the VASCOL 
baseline study. Normative values for Swedish men in the 
same age group were also collected from The Public 
Health Agency of Sweden, National Board of Health and 
Welfare and Statistics Sweden.
Wave 2: follow-up survey
In 2019, the Blekinge county demographic registers were 
used to identify all participants who were alive with a 
known address (n=1193). A new survey was sent out to all 
these participants. At Wave 2, 829 of the men replied to 
the initial survey within 2 weeks, and additional 78 men 
replied after a reminder, leading to 907/1193 (76%) of 
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men participated in Wave 2. See figure 2 for detailed 
information about data collection procedure. The postal 
survey consisted of questions and validated instruments 
regarding breathing, other cardiorespiratory- related 
symptoms, QoL, lifestyle, new medical conditions and 
any treatments for breathlessness. Most questions and 
instruments pertained to the experiences during the last 
2 weeks.
Planned data collection
Repeated waves will be conducted at four yearly inter-
vals, to enable examination of the change in partici-
pants’ breathlessness, other symptoms and QoL. Wave 
3 data collection will be conducted within 4 years, and 
the procedure and survey instruments will be similar to 
the first two waves. To broaden the VASCOL study and 
reach a bigger sample size, future data collections should 
also invite women to participate. Collected data will be 
cross- linked with nationwide Swedish registry data: Cause 
of Death Registry, Swedish Prescribed Drug Registry and 
National Patient Registry (see table 1). The Swedish 
registry databases have high coverage and completeness, 
but are limited in that they are not including any (or 
very limited) physiological variables and no symptoms or 
other patient reported outcomes. The VASCOL study and 
the registry databases will therefore complete each other.
Patient and public involvement
The follow- up survey was piloted on 10 people of similar 
age to the VASCOL study participants before the final 
survey was revised and administered. The pilot partici-
pants had the opportunity to add areas of research that 
they thought were relevant. Pilot participants also gave 
feedback on the layout and length of the survey as well 
as how the questions were asked. Minor linguistically and 
layout changes were done to the survey questions to fit 
the specific study participants.
FINDINGS TO DATE
Baseline characteristics of the VASCOL study are shown in 
table 2. The majority of the participants had hypertension 
(56%), and approximately one fifth had airflow limitation 
(forced expiratory volume in one second (FEV1)/forced 
vital capacity (FVC) <0.7). Only a small proportion had 
self- reported asthma (5%) or COPD (2%). One tenth 
(10%) reported diabetes. Also, approximately one tenth 
of the participants (13%) were everyday smokers, and 
the majority (54%) were former smokers. Around half of 
the participants were overweight (52%) and around one 
third (28%) obese. Participants in the VASCOL cohort 
had proportions similar to Swedish reference of norma-
tive values for similarly aged men concerning everyday 
Figure 1 Location of Blekinge in Sweden, Blekinge’s municipalities and main cities.
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smokers, height, FEV1/FVC and civil status. BMI values, 
educational level and proportion of former smokers were 
higher than the reference values.
Overall, the internal data completeness in the follow- up 
was high, with most instruments having 95% completion 
or more (table 3). Men participating in Wave 2 had an 
overall better health, healthier lifestyle and higher educa-
tion at baseline than those who did not participate in 
the follow- up (table 2). Wave 2 participants had a lower 
proportion of current smokers and a lower average 
number of pack- years. Those providing data for Wave 2 
had fewer comorbidities than those who did not, but who 
were still alive, other than hypertension which was equally 
prevalent.
Statistical methodology
A detailed statistical analysis plan will be prepared before 
each analysis. Relevant characteristics for each studies 
Figure 2 Flow chart of the recruitment for the VASCOL study. VASCOL, VAScular and Chronic Obstructive Lung disease.
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objective will be tabulated and compared using stan-
dard descriptive methods. Associations will be evaluated 
using regression models including logistic regression for 
categorical outcomes, and linear regression for contin-
uous outcomes. Kaplan- Meier, Cox proportional hazards 
regression and Fine- Grey regression (accounting for 
competing events) will be used for time- to- event analyses.
Sample size/power
The participants in the first follow- up of the VASCOL 
study (Wave 2) cover 45% of the population of men in 
the age group (n=2013) in Blekinge in 2019. Statistical 
power will be specified for each analysis.
STRENGTHS AND LIMITATIONS
Strengths of the VASCOL study include that it covers a 
large proportion of the eligible men in Blekinge. Over 
half (1302/2300) of all 65- year- old men in Blekinge 
county participated in the VASCOL baseline. The quality 
of the data was good, with a high- data completeness. The 
cohort is similar to men aged 65 in Sweden as a whole, 
which gives confidence regarding generalisability for 
men. However, a limitation is that we cannot generalise 
for women or younger men and future data collections 
should therefore include these groups. A limitation is the 
fact that nearly one- quarters (30%) of the participants 
did not participate in the follow- up (Wave 2). However, all 
participants in VASCOL baseline can be followed through 
the national registries, which can give some insight about 
the participants who did not participate in the follow- up 
(Wave 2). Participants in the follow- up study (Wave 2) was 
overall healthier at baseline than those not participating 
which might be explained by lower motivation to partic-
ipate in studies among those with poorer health or that 
less healthy participants have deceased between the base-
line and follow- up study.
The VASCOL study is to our knowledge, the most 
detailed prospective population- based study of breath-
lessness and other symptoms of cardiorespiratory diseases 
linked to registries with key information regarding health 
service utilisation and survival. Also, there are, to our 
knowledge, few population studies of older men’s symp-
toms and QoL. The VASCOL data are rich and consist of 
physiological measurements, blood samples and extensive 
survey data which make it possible to study many aspects 
of different symptoms and conditions. Sweden has a rich 
set of health- related registry data that can be cross- linked 
with the VASCOL data, and the variables collected in the 
VASCOL study can be studied as risk factors for outcomes 
such as morbidity, hospitalisation and mortality. The set 
of variables of the VASCOL data also enables studies of 
different conditions, long- term effect on breathlessness 
and other symptoms. The symptom data mostly consist 
of validated instruments, which enables comparison with 
other studies.
A limitation of the collected data is that former work-
places were not recorded, and pollution from dusty 
workplaces could possibly be a confounder of breathless-
ness. Also, cough was not measured, which is a common 
symptom of COPD. We therefore plan to include ques-
tions about former workplaces and cough in future 
follow- ups. Breathlessness was not assessed at baseline so 
the Global impression of change of breathlessness was 
used in Wave 2. This introduces the risk of recall bias in 
studies of changed breathlessness between Waves 1 and 2, 
and an inherently unknown baseline measurement error, 
but nevertheless is accepted as a valid approach. Further, 
for future VASCOL waves, the repeated self- report breath-
lessness measures will enable longitudinal examination 
from Wave 2.
Cardiorespiratory diseases, as well as breathlessness are 
common in the older population,3 9 and we believe that the 
VASCOL study can add valuable knowledge of the symp-
toms in the population. We will add knowledge regarding 
which symptoms predict worse clinical outcomes to iden-
tify people with a higher risk of mortality and morbidity, 
and as a potential therapeutic target.
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Swedish 65- year- 
old men
Self- reported data
Married 863 (71%) 1210 (93) 621 (73%) 242 (66%) 61%
Smoking status 1302 (100)
  Current smoker 168 (13%) 91 (10%) 77 (19%) 13%
  Former smoker 707 (54%) 514 (57%) 193 (49%) 36%
  Never smoker 427 (33%) 302 (33%) 125 (32%) 51%
Pack- years of 
smoking




520 (42%) 1218 (93) 381 (44%) 139 (38%) 25%
Hypertension 725 (56%) 1294 (99) 507 (56%) 218 (55%)
Diabetes 132 (10%) 1295 (99) 79 (9%) 53 (13%)
Asthma 71 (5%) 1285 (99) 47 (5%) 24 (6%) 9%*
COPD 29 (2%) 1205 (92) 13 (1%) 16 (4%)
Measured data by staff
Height 179±6.3 1285 (99) 179±6.1 179±7 178
Body mass index 
(kg/m2)
28.2±4.1 1275 (98) 28.1±4.0 28.5±4.4 26*
Underweight, BMI 
<18.5
1 (0.1%) 1 (0.1%) 0 (0%) 0.6%*
   Normal weight, 
BMI 18.5–24.9
260 (20%) 184 (21%) 76 (20%) 39%*
   Overweight, BMI 
25–29.9
661 (52%) 470 (53%) 191 (50%) 46%*
   Obesity, BMI 
>=30
352 (28%) 234 (26%) 118 (31%) 14%*
FEV1, % of predicted 87.2±15.1 1278 (98) 88.5±14.7 84.3±15.8
FVC, % of predicted 85.4±13.1 1278 (98) 86.3±13.0 83.4±13.1
FEV1/FVC < 0.7 242 (19%) 1295 (99) 157 (17%) 85 (22%) 18.2%†
Data are presented as mean±SD or frequency (rounded percentage). Normative values were collected from the publicly available databases 
of The Public Health Agency of Sweden (www.folkhalsomyndigheten.se), and Statistics Sweden (www.scb.se). The following variables are 
collected but not included in the table. Self- reported: exercise habits, alcohol consumption, tiredness, blood pressure medication, myocardial 
infarction, stroke, tia, angina pectoris, apnoea, snoring, osteoporosis, fractures, back pain, femur, radius, glaucoma, cataract, intermittent 
claudication. Measured by staff: blood pressure, pulse, weight, waist, swab measure, number of teeth, aortic diameter. Blood sample: Hb, 
HbA1C (% and later mmol), P- cystatin C, p- glucose, PT- GFR (CC estimate), S- CA, S- Na, S- K, S- creatinine, S- total cholesterol, ApoA1, ApoB.
*Reference based on available self- reported data for men 65 years or older.
†Reference based on available data for men 40 years or older.22
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity.
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Modified Medical Research Council (mMRC) 
breathlessness scale23
Functional impact of breathlessness (yes or no at 
each item)
97
mMRC- scale Intensity of functional impact of breathlessness (0–10 
at each item)
97
Dyspnoea-12 (D-12)24 Multidimensional breathlessness 95
Multidimensional Dyspnoea Profile (MDP) total20 Multidimensional breathlessness 77
MDP A1 unpleasantness Breathing unpleasantness 91
MDP perception score MDP A1 and five perception descriptors 79
MDP emotional response score Five emotional descriptors 89
Short form 12 item (version 2) Health survey14 Quality of life 98
Edmonton Symptom Assessment System, Revised 
(ESAS- r)25
Associated symptoms 98
FACIT- Fatigue26 Pathological tiredness 98
Hospital Anxiety and Depression Scale (HADS)27 Anxiety and depression 94
WHO Performance Status 0–428 Performance status 97
Custom items   
Global impression of change (GIC)29 in 
breathlessness since baseline
Seven categories from very much better to very much 
worse
99
Global impression of change (GIC)29 in health since 
baseline
Seven categories from very much better to very much 
worse
98
Activities given up because of breathlessness What activities have the participant giving up doe to 
breathlessness
91
Breathlessness unpleasantness Likert scale, four categories from mild to severe 93
Breathlessness duration How many years the participant have experience 
breathlessness
89
Proportion of awake time experiencing 
breathlessness
Five categories from none to whole time awake 91
Experiences temporary worsening breathlessness 
(how often, how long, when, causative factors).
4–6 categories at each question 94
Self- reported treatments of breathlessness Eight different possible treatments for breathlessness, 
and free text
89
Smoking status Four categories (everyday, sometimes, former and 
never smoker)
98
Smoking frequency Years of smoking, and number of cigarettes per day 92
Alcohol use Amount of wine, beer and strong spirit a week 84
Quality and duration of sleep Quality: 5 categories. Duration: 7 categories 99
Physical activity frequency Four categories, from daily to never 99
Physical activity intensity Four categories, from sedentary to intensity 97
Self- reported conditions Nineteen different possible diseases and conditions 95
Self- reported height and weight now cm and kg 99
Recall of height and weight at the age of 20 cm and kg 92
8 Olsson M, et al. BMJ Open 2021;11:e046473. doi:10.1136/bmjopen-2020-046473
Open access 
VASCOL study by external collaborators. Also, all requests must be approved by the 
Sweden’s national ethical review board.
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